Exhaled Hydrogen Sulfide Predicts Airway Inflammation Phenotype in COPD

References

1. 1.↵
   1. Vestbo J,
   2. Hurd SS,
   3. Agusti AG,
   4. Jones PW,
   5. Vogelmeier C,
   6. Anzueto A,
   7. et al

   . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187(4):347–365.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Salvi SS,
   2. Barnes PJ

   . Chronic obstructive pulmonary disease in non-smokers. Lancet 2009;374(9691):733–743.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Pizzichini E,
   2. Pizzichini MM,
   3. Gibson P,
   4. Parameswaran K,
   5. Gleich GJ,
   6. Berman L,
   7. et al

   . Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998;158(5 Pt 1):1511–1517.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Rabe KF,
   2. Hurd S,
   3. Anzueto A,
   4. Barnes PJ,
   5. Buist SA,
   6. Calverley P,
   7. et al

   . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532–555.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Halpin D

   . NICE guidance for COPD. Thorax 2004;59(3):181–182.

   OpenUrlFREE Full Text
6. 6.↵
   1. Bhowmik A,
   2. Seemungal TA,
   3. Sapsford RJ,
   4. Wedzicha JA

   . Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55(2):114–120.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Gorska K,
   2. Krenke R,
   3. Korczynski P,
   4. Kosciuch J,
   5. Domagala-Kulawik J,
   6. Chazan R

   . Eosinophilic airway inflammation in chronic obstructive pulmonary disease and asthma. J Physiol Pharmacol 2008;59 (Suppl 6):261-270.

   OpenUrlPubMed
8. 8.↵
   1. Brightling CE,
   2. McKenna S,
   3. Hargadon B,
   4. Birring S,
   5. Green R,
   6. Siva R,
   7. et al

   . Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005;60(3):193–198.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Chen YH,
   2. Yao WZ,
   3. Geng B,
   4. Ding YL,
   5. Lu M,
   6. Zhao MW,
   7. Tang CS

   . Endogenous hydrogen sulfide in patients with COPD. Chest 2005;128(5):3205–3211.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.
    1. Toombs CF,
    2. Insko MA,
    3. Wintner EA,
    4. Deckwerth TL,
    5. Usansky H,
    6. Jamil K,
    7. et al

    . Detection of exhaled hydrogen sulphide gas in healthy human volunteers during intravenous administration of sodium sulphide. Br J Clin Pharmacol 2010;69(6):626–636.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Insko MA,
    2. Deckwerth TL,
    3. Hill P,
    4. Toombs CF,
    5. Szabo C

    . Detection of exhaled hydrogen sulphide gas in rats exposed to intravenous sodium sulphide. Br J Pharmacol 2009;157(6):944–951.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Chung KF

    . Hydrogen sulfide as a potential biomarker of asthma. Expert Rev Respir Med 2014;8(1):5–13.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Chen Y,
    2. Wang R

    . The message in the air: hydrogen sulfide metabolism in chronic respiratory diseases. Respir Physiol Neurobiol 2012;184(2):130–138.

    OpenUrlCrossRefPubMed
14. 14.↵
    Chinese Medical Association Respiratory Diseases Chronic Obstructive Pulmonary Disease Group. Chronic obstructive pulmonary disease treatment guidelines (2007 revision). J Tuberculosis Respir Dis 2007;30(1):8–17.

    OpenUrl
15. 15.↵
    1. Mahler DA,
    2. Wells CK

    . Evaluation of clinical methods for rating dyspnea. Chest 1988;93(3):580–586.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Jones PW,
    2. Quirk FH,
    3. Baveystock CM

    . The St George's Respiratory Questionnaire. Respir Med 1991;85 Suppl B:25-31; discussion 33-27.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Mu K,
    2. Liu S

    . [National lung function normal value compilation]. Beijing: Beijing Medical University, Peking Union Medical College Union Publishing House, 1990.
18. 18.↵
    1. Beier J,
    2. Beeh KM,
    3. Kornmann O,
    4. Buhl R

    . Induced sputum methodology: validity and reproducibility of total glutathione measurement in supernatant of healthy and asthmatic individuals. J Lab Clin Med 2004;144(1):38–44.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Loppow D,
    2. Schleiss MB,
    3. Kanniess F,
    4. Taube C,
    5. Jörres RA,
    6. Magnussen H

    . In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 2001;95(2):115–121.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Saetta M,
    2. Di Stefano A,
    3. Maestrelli P,
    4. Turato G,
    5. Ruggieri MP,
    6. Roggeri A,
    7. et al

    . Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150(6 Pt 1):1646–1652.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Snoeck-Stroband JB,
    2. Lapperre TS,
    3. Gosman MM,
    4. Boezen HM,
    5. Timens W,
    6. ten Hacken NH,
    7. et al

    . Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. Eur Respir J 2008;31(1):70–77.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Berry MA,
    2. Hargadon B,
    3. McKenna S,
    4. Shaw D,
    5. Green RH,
    6. Brightling CE,
    7. et al

    . Observational study of the natural history of eosinophilic bronchitis. Clin Exp Allergy 2005;35(5):598–601.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Saha S,
    2. Brightling CE

    . Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2006;1(1):39–47.

    OpenUrlPubMed
24. 24.↵
    1. Chanez P,
    2. Vignola AM,
    3. O'Shaugnessy T,
    4. Enander I,
    5. Li D,
    6. Jeffery PK,
    7. Bousquet J

    . Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997;155(5):1529–1534.

    OpenUrlPubMedWeb of Science
25. 25.↵
    1. Sun Y,
    2. Wang XM,
    3. Chen YH,
    4. Zhu RX,
    5. Liao CC

    . Exhaled hydrogen sulfide in patients with chronic obstructive pulmonary disease and its correlation with exhaled nitric oxide. Chin Med J (Engl) 2013;126(17):3240–3244.

    OpenUrlPubMed
26. 26.↵
    1. Chen YH,
    2. Wang PP,
    3. Wang XM,
    4. He YJ,
    5. Yao WZ,
    6. Qi YF,
    7. Tang CS

    . Involvement of endogenous hydrogen sulfide in cigarette smoke-induced changes in airway responsiveness and inflammation of rat lung. Cytokine 2011;53(3):334–341.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Han W,
    2. Dong Z,
    3. Dimitropoulou C,
    4. Su Y

    . Hydrogen sulfide ameliorates tobacco smoke-induced oxidative stress and emphysema in mice. Antioxid Redox Signal 2011;15(8):2121–2134.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Shen N,
    2. Yao WZ,
    3. Liu Z,
    4. Wang XH,
    5. Hao ZT,
    6. Liu XF

    . [Correlation of the quality of life with the inspiratory capacity in patients with chronic obstructive pulmonary disease]. Zhonghua Jie He He Hu Xi Za Zhi 2010;33(4):261–264.

    OpenUrlPubMed
29. 29.↵
    1. O'Donnell DE,
    2. Guenette JA,
    3. Maltais F,
    4. Webb KA

    . Decline of resting inspiratory capacity in COPD: the impact on breathing pattern, dyspnea, and ventilatory capacity during exercise. Chest 2012;141(3):753–762.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Vernooy JH,
    2. Küçükaycan M,
    3. Jacobs JA,
    4. Chavannes NH,
    5. Buurman WA,
    6. Dentener MA,
    7. Wouters EF

    . Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002;166(9):1218–1224.

    OpenUrlCrossRefPubMedWeb of Science